This website is for Healthcare Professionals only.
EFFICACY RESULTS FOR TEPKINLY
Subcutaneous TEPKINLY offers patients a chance at deep and durable* responses and long-term survival1-3*†
In the EPCORE™ NHL-1 trial, TEPKINLY achieved1,2:
*The median follow-up time was 10.7 months (range: 0.3-17.9 months).1
†Overall survival (OS) was a secondary endpoint in the study. After a median follow-up time of 20 months (range: 0.3+-28.2), the mOS for patients on TEPKINLY was 19.4 months (11.7-NR).2,3
Deep and durable responses, with an mDOR of 15.5 (95% CI, 9.7-NR) months1,2
- In patients whose best response is CR, mDOR not reached (95% CI, 12.0 months-NR)
Subcutaneous TEPKINLY demonstrated consistent efficacy across a broad range of patients1,2,4
Consistent response across key subgroups1,2,4
aPrespecified analysis.1
bPercent of patients in the LBCL cohort in the dose-expansion phase of EPCORE NHL-1(N=157). Median follow-up of 10.7 months.1,2
[INCLUDE SAFETY INFORMATION PER LOCAL REGULATIONS]
I would like to request a meeting with an AbbVie representative.
Understand the safety profile of TEPKINLY.
CAR T=chimeric antigen T cell; CI=confidence interval; CR=complete response; DLBCL=diffuse large B-cell lymphoma; mDOCR=median duration of complete response; mDOR=median duration of response; mOS=median overall survival; NHL=non-Hodgkin lymphoma; NR=not reached; ORR=overall response rate.
TEPKINLY as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
References: 1. TEPKINLY Summary of Product Characteristics. AbbVie Inc. 2. Thieblemont C, Phillips T, Ghesquieres H, et al. Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell–engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial. J Clin Oncol. Published online December 22, 2022. doi:10.1200/JCO.22.01725 3. Jurczak W, Guesquieres W, Karimi Y, et al. Longer follow-up from the pivotal EPCORE NHL-1 trial reaffirms subcutaneous epcoritamab induces deep, durable remissions in patients with relapsed/refractory large B-cell lymphoma. Hemasphere. 2023;7(suppl):e081065c. doi:10.1097/01.HS9.0000971368.08106.5c 4. Data on file. AbbVie Inc.
ALL-EPCOR-230034